18.55
前日終値:
$18.48
開ける:
$18.51
24時間の取引高:
2.17M
Relative Volume:
1.31
時価総額:
$1.64B
収益:
$217.42M
当期純損益:
$-243.25M
株価収益率:
-6.6364
EPS:
-2.7952
ネットキャッシュフロー:
$-278.35M
1週間 パフォーマンス:
+4.86%
1か月 パフォーマンス:
-8.30%
6か月 パフォーマンス:
-10.47%
1年 パフォーマンス:
+85.69%
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
名前
Syndax Pharmaceuticals Inc
セクター
電話
781-419-1400
住所
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
SNDX
Syndax Pharmaceuticals Inc
|
18.55 | 1.64B | 217.42M | -243.25M | -278.35M | -2.7952 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-16 | 再開されました | H.C. Wainwright | Buy |
| 2025-09-10 | 再開されました | Stifel | Buy |
| 2025-09-04 | 再開されました | Guggenheim | Buy |
| 2025-08-05 | 繰り返されました | BTIG Research | Buy |
| 2025-07-10 | 開始されました | Goldman | Buy |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-06-28 | 開始されました | Jefferies | Buy |
| 2024-01-31 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | 開始されました | Mizuho | Buy |
| 2023-10-25 | 開始されました | BofA Securities | Buy |
| 2023-10-11 | 開始されました | Goldman | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-07-11 | 開始されました | Guggenheim | Buy |
| 2023-04-17 | 再開されました | BTIG Research | Buy |
| 2023-01-31 | 開始されました | Stifel | Buy |
| 2023-01-03 | 開始されました | JP Morgan | Overweight |
| 2022-07-28 | 再開されました | B. Riley Securities | Buy |
| 2022-04-11 | 開始されました | H.C. Wainwright | Buy |
| 2022-02-15 | 開始されました | Goldman | Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-05-25 | 開始されました | Citigroup | Buy |
| 2021-02-18 | 開始されました | B. Riley Securities | Buy |
| 2020-12-03 | 開始されました | Stifel | Buy |
| 2020-05-22 | アップグレード | Citigroup | Neutral → Buy |
| 2020-05-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-05-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-03-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-01-04 | 開始されました | Robert W. Baird | Outperform |
| 2018-01-05 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | 開始されました | FBR & Co. | Outperform |
| 2017-03-02 | 開始されました | Instinet | Buy |
| 2016-10-07 | 開始されました | Guggenheim | Buy |
| 2016-03-28 | 開始されました | Citigroup | Buy |
| 2016-03-28 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-03-28 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Syndax Pharmaceuticals Inc (SNDX) 最新ニュース
Syndax Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript - GuruFocus
Syndax Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Eventide Asset Management LLC Has $26.01 Million Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (SNDX) Is Up 5.2% After Strong All-Oral Revuforj SAVE Trial DataWhat's Changed - Yahoo Finance
Voss Capital LP Buys Shares of 125,000 Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Rhenman & Partners Asset Management AB Sells 87,000 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
SNDX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Syndax (SNDX) CMO sells 65,515 shares, retains 60,885 and large options - Stock Titan
SNDX (NASDAQ) Rule 144 notice: Director-linked sale of 31,235 shares - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
SNDX Stock Price, Quote & Chart - ChartMill
[144] Syndax Pharmaceuticals Inc SEC Filing - Stock Titan
Syndax showcases revuforj (revumenib) data at EHA 2026 - grafa.com
Syndax (SNDX) Reveals Encouraging Results from SAVE Trial for AM - GuruFocus
Syndax Pharmaceuticals: The Duration Expansion Story Is Being Underpriced (NASDAQ:SNDX) - Seeking Alpha
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026 - The Manila Times
Leukemia drug revumenib shows up to 97% remission in EHA 2026 data - Stock Titan
Syndax Pharmaceuticals Announces Publication of Save Data on Revuforj in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML - marketscreener.com
SNDX6417984 Bond Coupon Analysis — Rate & Payments - TradingView
Syndax Pharmaceuticals (NASDAQ: SNDX) issues $250M 2.25% convertible notes due 2031 - Stock Titan
Syndax (NASDAQ: SNDX) investors back 2026 equity plan and new ESPP - Stock Titan
Syndax Pharmaceuticals, Inc. Bonds — Corporate Bond Rates - TradingView
Syndax Pharmaceuticals Inc Bonds — Corporate Bond Rates - TradingView
Syndax Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:SNDX) - MarketBeat
SNDX6417984 Bond Analysis — Key Metrics - TradingView
Transcript : Syndax Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 02 - marketscreener.com
SNDX: Revuforj's clinical success and expanding pipeline drive growth, with new capital fueling future innovation - TradingView
Syndax Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
SNDX6417984 Bond Price and Chart — FINRA:SNDX6417984 - TradingView
Price-Driven Insight from (SNDX) for Rule-Based Strategy - Stock Traders Daily
A Look At Syndax Pharmaceuticals (SNDX) Valuation After Recent Share Price Weakness - Sahm
Syndax Pharmaceuticals prices $250M senior convertible notes - MSN
Syndax Pharmaceuticals prices $250 million convertible notes By Investing.com - Investing.com Australia
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Syndax (SNDX) Launches $250M Convertible Senior Note Offering - GuruFocus
Syndax Pharmaceuticals (SNDX) Faces Selling Pressure, Testing Near-Term Support LevelsLiquidity Order Flow - newsline.com
Syndax Pharmaceuticals prices $250 million convertible notes - Investing.com UK
Goldman Sachs Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Syndax Pharmaceuticals Prices $250 Million Convertible Senior Notes - TipRanks
Syndax Prices $250 Million 2.25% Convertible Notes Due 2031 in Private Placement - TradingView
Syndax (NASDAQ: SNDX) raises $250M via 2.25% convertible notes due 2031 - Stock Titan
Syndax Pharmaceuticals Announces $250 Million Private Placement of Convertible Senior Notes - Quiver Quantitative
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes - The Manila Times
Syndax lines up $250M in 2.25% debt swappable into its stock - Stock Titan
H.C. Wainwright reiterates Syndax Pharmaceuticals stock rating on ASCO data - Investing.com Canada
Stifel reiterates Syndax Pharmaceuticals stock rating on ASCO data By Investing.com - Investing.com Canada
Syndax (SNDX) CFO sells 1,177 shares to cover RSU tax withholding - Stock Titan
Syndax Pharmaceuticals (SNDX) CEO sells shares to cover tax obligations - Stock Titan
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data - The Manila Times
Small leukemia study finds 90% 2-year survival with revumenib after transplant - Stock Titan
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026 - The Manila Times
Syndax Pharmaceuticals Inc (SNDX) 財務データ
収益
当期純利益
現金流量
EPS
Syndax Pharmaceuticals Inc (SNDX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Botwood Nicholas A.J. | Head of R&D, CMO |
Jun 11 '26 |
Option Exercise |
13.82 |
22,515 |
311,157 |
95,165 |
| Botwood Nicholas A.J. | Head of R&D, CMO |
Jun 11 '26 |
Sale |
18.00 |
34,280 |
617,040 |
60,885 |
| Botwood Nicholas A.J. | Head of R&D, CMO |
Jun 12 '26 |
Sale |
18.14 |
31,235 |
566,603 |
60,885 |
大文字化:
|
ボリューム (24 時間):